Tenofovir, Emtricitabine, and Tenofovir Diphosphate in Dried Blood Spots for Determining Recent and Cumulative Drug Exposure
- 1 February 2013
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 29 (2), 384-390
- https://doi.org/10.1089/aid.2012.0089
Abstract
Tenofovir (TFV) disoproxil fumarate (TDF)±emtricitabine (FTC) are widely used for HIV treatment and chemoprophylaxis, but variable adherence may lead to suboptimal responses. Methods that quantify adherence would allow for interventions to improve treatment and prevention outcomes. Our objective was to characterize the pharmacokinetics of TFV-diphosphate (TFV-DP) and FTC-triphosphate (FTC-TP) in red blood cells (RBCs) and peripheral blood mononuclear cells (PBMCs); to extend the RBC analysis to dried blood spots (DBSs); and to model how RBC/DBS monitoring could inform recent and cumulative drug exposure/adherence. Blood samples were collected from 17 HIV-negative adults at 5 visits over a 30-day pharmacokinetics study of daily oral TDF/FTC. Dosing was discontinued on day 30 and blood was collected on days 35, 45, and 60 during the washout period. Plasma/RBCs/PBMCs/DBSs were all quantified by liquid chromatography/tandem mass spectrometry. DBSs were paired with RBCs and plasma for comparisons. The median (interquartile range) RBC TFV-DP half-life was 17.1 (15.7–20.2) versus 4.2 (3.7–5.2) days in PBMCs. At steady state, TFV-DP was 130 fmol/106 RBCs versus 98 fmol/106 PBMCs. FTC-TP was not quantifiable in most RBC samples. TFV-DP in RBCs versus DBSs yielded an r2=0.83. TFV-DP in DBSs was stable at −20°C. Simulations of TFV-DP in RBCs/DBSs, when dosed from one to seven times per week, demonstrated that each dose per week resulted in an average change of approximately 19 fmol/106 RBCs and 230 fmol/punch. TFV and FTC in plasma versus DBSs was defined by y=1.4x; r2=0.96 and y=0.8x; r2=0.99, respectively. We conclude that DBSs offer a convenient measure of recent (TFV/FTC) and cumulative (TFV-DP in RBCs) drug exposure with potential application to adherence monitoring.Keywords
This publication has 33 references indexed in Scilit:
- Unraveling the divergent results of pre-exposure prophylaxis trials for HIV preventionAIDS, 2012
- Long-Term Effectiveness of Highly Active Antiretroviral Therapy on the Survival of Children and Adolescents with HIV Infection: A 10-Year Follow-Up StudyClinical Infectious Diseases, 2008
- Determination of rifampicin in human plasma and blood spots by high performance liquid chromatography with UV detection: A potential method for therapeutic drug monitoringJournal of Pharmaceutical and Biomedical Analysis, 2007
- Evidence and Possible Consequences of the Phosphorylation of Nucleoside Reverse Transcriptase Inhibitors in Human Red Blood CellsAntimicrobial Agents and Chemotherapy, 2007
- Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding AssaysPharmaceutical Research, 2007
- Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapyAIDS, 2007
- The Elusive Gold StandardJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometryRapid Communications in Mass Spectrometry, 2005
- Intracellular Pharmacokinetics of Tenofovir Diphosphate, Carbovir Triphosphate, and Lamivudine Triphosphate in Patients Receiving Triple-Nucleoside RegimensJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Gestation-induced changes in lamotrigine pharmacokinetics: A monotherapy studyNeurology, 2004